Navigation Links
Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts
Date:8/3/2010

ROCHESTER, Minn. - In recent years, advances in CT scanner technology have made perfusion computed tomography (CT) imaging an important diagnostic tool for patients with suspected stroke. Now, researchers at Mayo Clinic are working to reduce radiation dosages used to acquire perfusion and other CT images. Mayo Clinic medical physicist Cynthia McCollough, Ph.D., and her group of researchers presented their findings related to CT dose reduction at the 52nd Annual Meeting of the American Association of Physicists in Medicine on July 20 in Philadelphia. The presentation was entitled "20-Fold Dose Reduction Using a Gradient Adaptive Bilateral Filter: Demonstration Using in Vivo Animal Perfusion CT."

"We believe in the clinical value of perfusion CT, and though there is no documented risk of injury at the currently prescribed radiation levels, we are trying to lower the dose for the benefit of patients," says Dr. McCollough, diagnostic radiologist, Mayo Clinic.

The As Low As Reasonably Achievable, or ALARA, principle has always guided Mayo Clinic's approach to the dosages of radiation used to acquire CT images. Dr. McCollough's team has been experimenting with a newly created image-processing algorithm that produces high-quality perfusion CTs with up to 20 times less the radiation used under existing protocols. Depending on the diagnostic application, a perfusion CT exam takes about 30 seconds to scan the tissue multiple times after iodine has been injected. This technique detects changes in blood volume and flow that reveal injuries to vessels or a tumor's response to treatment. Information from each consecutive scan is then digitally cross-referenced with other images taken during the exam to improve image quality and reduce distortions.

Thus far, the new perfusion CT algorithms have proved effective in animal models, and Dr. McCollough's team has begun looking at ways to introduce the methodologies into clinical practice.

"When we use very low doses of radiation to acquire a CT, image graininess can significantly decrease the value of the exam," says the study's first author, Juan Carlos Ramirez Giraldo, Mayo Clinic. "With this new algorithm, we are able to maintain the image quality by cross-referencing it with other images collected during the exam."

In related efforts, using one of the latest CT scanners on the market, Mayo Clinic already has other advanced algorithms as part of its clinical practice. A team of radiologists and physicists have recently implemented a new routine head CT protocol that cuts radiation dose by nearly 50 percent. While the American College of Radiology allows its accredited facilities to use head CT doses up to approximately 75 mGy, Mayo Clinic's newly introduced patient protocol uses a dose of only 38 mGy. This dose reduction is particularly significant as head CT exams are one of the most commonly performed CT procedures.

When asked how the new head CT protocol is changing clinical practice, neuroradiologist David DeLone, M.D., Mayo Clinic, says, "patients aren't aware that anything has changed, and as radiologists looking at a study, we don't know anything has changed. Yet, we are obtaining high-quality images, more consistently and in shorter times, while exposing patients to about half of the radiation dose. It's a win-win for everyone."


'/>"/>

Contact: Rebecca Finseth
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. The West Clinic Joins Cancer Clinics of Excellence (CCE)
2. Stethoscope App gives iPhone New Clinical Skills
3. Mayo Clinic responsible for $22 billion in economic impact, including $9.6 billion in Minnesota
4. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
7. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
11. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: